Development of a nano-bioplatform for SARS-CoV-2 specific antigens detection

Lateral Flow Immunoassay (LFIA) has been employed for the development of rapid, low-cost, and relatively simple devices for Covid-19 diagnosis. The proposed approach reports the use of the antibody labeled by Gold nanoparticles for the simultaneous detection of Nucleocapsid protein and Spike protein. A comparison with the results obtained by conventional analytical methods (PCR) has been considered in a significant number of nasopharyngeal swabs; 48 and 26 samples from positive and negative individuals respectively. This research provides the basis for the development of a more efficient antigenic test for SARS-Co V-2 detection as a low-cost and quick pre-screening tool.